The USA's Tekmira Pharmaceuticals has entered a research collaboration with drug major Bristol-Myers Squibb, focused on using its stable nucleic-acid lipid particle technology to deliver small interfering RNAs to specific organs and tissues outside of the liver. The relationship between the two builds upon earlier work conducted at B-MS using siRNA delivery technology provided by privately-held Protiva Biotherapeutics, which combined its business with Tekmira in May. The initial collaboration with B-MS focused on validating certain gene targets using siRNAs provided by the drug major and employed a number of different formulations involving SNALPs, Tekmira's proprietary lipid nanoparticle technology for the delivery of RNAs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze